Pharma BD Deal Intelligence
A $160M asset buy became the potentiator inside Vertex's next-gen CF blockbuster, Alyftrek — one of the best-aged small bolt-ons in the CF space.
Full analysis, sources & comparables →Vertex fine-tunes its CF portfolio with the Concert deal, paying $160M cash plus $90M in milestones to absorb the only competing CFTR potentiator in clinical…
Vertex bought Concert's CF drug for $160M upfront; Concert shares soared 34.7% to $13.00 in pre-market trading, a validation of its deuterium chemistry…
While Vertex gears up for next-generation CF treatment built on the deutivacaftor backbone, Trikafta sales reached $8.9B in 2023, validating the franchise…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Vertex acquired worldwide development and commercialization rights to CTP-656, Concert's deuterated CFTR potentiator, for $160M upfront cash plus up to $90M in regulatory/reimbursement milestones (U.S., UK/Germany/France). The longer half-life potentiator was intended to enable once-daily dosing in CF triple-combination regimens. Closed July 2017.
A $160M asset buy became the potentiator inside Vertex's next-gen CF blockbuster, Alyftrek — one of the best-aged small bolt-ons in the CF space.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. (this deal) | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. | 2026 | $10.0B | 68 |
| Vertex Pharmaceuticals Incorporated / ViaCyte Inc. | 2022 | $320M | 60 |
← Browse all deals · How we score deals
More: 2017 deals · Vertex Pharmaceuticals Incorporated deals · Respiratory deals